Halozyme Therapeutics, Inc. (HALO) stock is up 53.26% over the last 12 months, and the average rating from Wall Street analysts is a Buy. InvestorsObserver’s proprietary ranking system, gives HALO stock a score of 33 out of a possible 100.
That rank is mainly influenced by a fundamental score of 25. In addition to the average rating from Wall Street analysts, HALO stock has a mean target price of $49.00. This means analysts expect the stock to add 15.21% over the next 12 months. HALO's rank also includes a long-term technical score of 36. The short-term technical score for HALO is 37.
HALO has an Overall Score of 33. Find out what this means to you and get the rest of the rankings on HALO!
Halozyme Therapeutics, Inc. (HALO) stock is higher by 0.73% while the S&P 500 is down -0.16% as of 2:00 PM on Tuesday, Sep 7. HALO is up $0.31 from the previous closing price of $42.22 on volume of 341,896 shares. Over the past year the S&P 500 is higher by 35.91% while HALO is up 53.26%. HALO earned $1.56 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 27.2.
Click Here to get the full Stock Report for Halozyme Therapeutics, Inc. stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter
